The Comorbidity of Major Depression and Anxiety Disorders: Recognition and Management in Primary Care

Robert M. A. Hirschfeld, M.D.

Depression and anxiety frequently co-occur, especially in primary care settings. These co-occurrences manifest themselves in several ways and have different clinical courses. This review was written to help the clinician to identify what is and is not important in the diagnosis and treatment of patients with comorbid depression and anxiety in the primary care setting. The scope of this review is limited to major depression and not other forms of depression such as bipolar depression or dysthymic disorder. Literature was reviewed by 2 methods: (1) a MEDLINE search (1980–2001) using key words depression, depressive disorders, and anxiety disorders; comorbidity was also searched with individual anxiety diagnoses; and (2) direct search of psychiatry, primary care, and internal medicine journals over the past 5 years.

Results: Between 10% and 20% of adults in any given 12-month period will visit their primary care physician during an anxiety or depressive disorder episode (although typically for a nonpsychiatric complaint); more than 50% of these patients suffer from a comorbid second depressive or anxiety disorder. The presence of depressive/anxiety comorbidity substantially increases medical utilization and is associated with greater chronicity, slower recovery, increased rates of recurrence, and greater psychosocial disability. Typically, long-term treatment is indicated, although far less research is available to guide treatment decisions. Selective serotonin reuptake inhibitor antidepressants are the preferred treatment based on efficacy, safety, and tolerability criteria. Knowledge of their differential clinical and pharmacokinetic profiles can assist in optimizing treatment.

Conclusion: Increased recognition of the high prevalence and negative psychosocial impact of depression and anxiety disorder comorbidity will lead to more effective treatment. While it is hoped that early and effective intervention will yield long-term benefits, research is needed to confirm this.

(Primary Care Companion J Clin Psychiatry 2001;3:244–254)
Comorbidity of Major Depression and Anxiety Disorders

The case history summarized above illustrates some of the difficulties faced by a physician in the primary care setting in recognizing and diagnosing comorbid anxiety and depressive disorders. First, the patient frequently presents with a somatic complaint; second, the symptoms of anxiety and depression are typically intermingled with real-life problems; and third, the patient often has little or no insight into the psychological issues. The dilemma of diagnosis, therefore, lies in maintaining an appropriate index of suspicion for the presence of an anxiety or depression diagnosis amid the constant background flow of somatic complaints. An index of suspicion and a familiarity with common patterns of anxiety and depression comorbidity are crucial to the appropriate recognition and treatment of these disorders in the primary care setting.

Comorbid major depression and anxiety typically present as 1 of 4 clinical combinations (Figure 1). The patient may meet criteria for an anxiety disorder diagnosis, but suffer from only subsyndromal levels of depression symptoms (see Figure 1, panel A). Alternatively, a patient may meet criteria for major depression, but suffer from only subsyndromal levels of anxiety symptoms (panel B). Thirdly, a patient may present with a full-fledged diagnosis of both an anxiety disorder and major depression (panel C). Finally, a patient may present with symptoms of both anxiety and depression, neither of which is severe enough to meet criteria for a diagnosis (panel D). This latter presentation is referred to as “mixed anxiety-depression.” Surveys of patients in primary care have reported the prevalence of mixed anxiety-depression to be in the range of 1% to 5%. These symptomatic but subsyndromal patients have been found to have a level of disability that is closer to that of patients who meet full diagnostic criteria for major depressive disorder or an anxiety disorder than to that of patients reporting no anxious-depressive symptomatology. The few studies that have prospectively followed these patients report that approximately 1 in 5 will develop a full-blown major depression within the next 12 months.

THE EPIDEMIOLOGY OF COMORBIDITY

In the past decade, large surveys conducted both in the community and in the primary care setting have established one simple but clinically important fact: depression that is not complicated by comorbidity is the exception, not the rule.
Figure 2 shows the prevalence rates in the community, in any given 12-month period, of individual depression and anxiety disorders. These data confirm that depression and anxiety disorders occur at rates that exceed other common medical illnesses such as hypertension, diabetes, or asthma. Among patients in the community who meet criteria for major depression, approximately 50% are also suffering from an anxiety disorder (Figure 3).

The results shown in Figure 3 are from epidemiologic surveys conducted in the community. But what is the likelihood that a patient who presents in the primary care setting with major depression or an anxiety disorder will also be suffering from a second depressive/anxiety disorder? Large primary care surveys suggest that such comorbidity is even higher in primary care than in the community.10,16

Overall, more than 75% of patients diagnosed with depression in a primary care setting suffer from a current anxiety disorder.16

Calculation of odds ratios is a useful method of estimating the likelihood of having a second, concurrent diagnosis given the presence of depression and/or an anxiety disorder. In someone diagnosed with major depression, there is a 3.3-fold to 8.2-fold increased likelihood that the patient is also suffering from a comorbid anxiety disorder (Figure 4).15 Conversely, if a patient carries an anxiety disorder diagnosis, there is very high likelihood (odds ratios from 7 to 62) that the patient will develop major depression within the following year (Figure 5).
These data help to quantify the level of diagnostic awareness that a physician must maintain. Given such high odds ratios, it should be routine clinical practice to screen for the presence of major depression given the presence of an anxiety disorder and vice versa.

Put another way, the presence of an anxiety disorder is the single biggest clinical risk for the development of depression. A common scenario appears to be the following: exposure to significant life stressors such as interpersonal conflict, some type of personal loss, or some type of life threat leads to clinical levels of anxiety. The experience of anxiety may, in turn, serve as a compounding stressor that facilitates further decompensation, leading (especially in patients with a genetic/familial diathesis) to major depression. Time-series analyses confirm that the new onset of an anxiety disorder puts a patient at significantly increased risk of developing major depression in the ensuing year. This risk is extremely high (more than 20-fold) in the case of panic disorder and generalized anxiety disorder (GAD). The risk levels off after the first year, but continues to persist as a 2-fold or greater risk for many years after that.

**WHAT ARE THE CONSEQUENCES OF COMORBIDITY?**

Patients who have depression and anxiety comorbidity have higher severity of illness, higher chronicity, and significantly greater impairment in work functioning, psychosocial functioning, and quality of life than patients not suffering from comorbidity.

One of the most important clinical reasons to screen for comorbidity is that unrecognized depression/anxiety comorbidity is associated with an increased rate of psychiatric hospitalization and an increased rate of suicide attempts. For example, suicide attempt rates are 70% higher in patients with comorbid major depression and panic disorder than in those with major depression alone and more than 4 times higher than in patients suffering from uncomplicated panic disorder. Among anxiety disorders, posttraumatic stress disorder (PTSD) has the highest rate of comorbid psychiatric disorders, including alcohol abuse. Comorbid depression and anxiety have also been shown to significantly increase the suicide attempt risk above what is contributed by major depression alone. The results of a large national survey found that anxiety comorbidity was associated with a 2.5-fold increased likelihood of hospitalization, with patients suffering from concurrent panic disorder being most at risk (odds ratio = 3.2).

The presence of comorbidity increases the chronicity of each disorder, slows recovery, and increases the likelihood of a recurrence once the patient has recovered. As will be discussed in a later section, the chronicity/recurrence risk associated with comorbidity often requires that the patient be treated for a longer time with medication. Such patients must be educated about the early warning signs of these highly recurrent disorders.

**SCREENING FOR DEPRESSION AND ANXIETY: THE PRIME-MD**

The presence of an anxiety disorder may serve to mask the presence of depression and vice versa. This is partly due to the overlap of symptoms in these disorders. For example, insomnia and loss of appetite may be symptoms of both illnesses. Incomplete diagnosis may be due to the assumption that once the first diagnosis has been made, one’s diagnostic work is accomplished. As noted previously, all of the available epidemiologic data suggest that the presence of one disorder significantly increases the likelihood that the other disorder may also be present.

Relatively few scales are available that screen for depression and anxiety and have been validated in the primary care setting. Scales meeting these criteria include the Primary Care Evaluation of Mental Disorders (PRIME-MD), the Symptom Driven Diagnostic System for Primary Care (SDDS-PC), and the Center for Epidemiologic Studies Depression Scale (CES-D). The CES-D is a subscale of a larger, population-based research screening tool, the General Health Questionnaire (GHQ).

Table 1 gives the depression and anxiety screening questions from the Patient Health Questionnaire (PHQ), the patient-rated module of the PRIME-MD. The positive predictive value of the PRIME-MD for detecting major depression and anxiety disorders in the primary care setting is above 90%. Setting the threshold score higher yields increased diagnostic specificity, but lowers the sensitivity (i.e., more cases are missed). For example, a score of 9 on the first 9 items, which screen for depression, is associated with a diagnostic sensitivity of 95% and a specificity of 84%, while a score of 12 is associated with a sensitivity of 83% and a specificity of 92%. While screening is no substitute for diagnosis, it can serve to identify, to a high probability, which patients are likely to have a diagnosis.

**THE MASKING EFFECT OF MEDICAL COMORBIDITY**

The depression/anxiety comorbidity story would not be complete without emphasizing the additional complication of general medical comorbidity. Patients in primary care who have a depression or anxiety disorder diagnosis report an average of 2 to 3 concurrent chronic medical illnesses, a rate that is more than double that reported by patients who do not suffer from depression or anxiety. Conversely, patients with diagnosed general medical illnesses, especially chronic conditions, are at significantly increased risk for developing depression.
Table 1. Primary Care Evaluation of Mental Disorders (PRIME-MD) Patient Health Questionnaire Screener

Name: ___________________________ Date: __________________

Over the last 2 weeks, how often have you been bothered by any of the following problems?

0 = Not at all
1 = Several days
2 = More than half the days
3 = Nearly every day

1. Little interest or pleasure in doing things
2. Feeling down, depressed, or hopeless
3. Trouble falling or staying asleep, or sleeping too much
4. Feeling tired or having little energy
5. Poor appetite or overeating
6. Feeling bad about yourself—or that you are a failure or have let yourself or your family down
7. Trouble concentrating on things, such as reading the newspaper or watching television
8. Moving or speaking so slowly that other people could have noticed. Or the opposite—being so fidgety or restless that you have been moving around a lot more than usual
9. Thoughts that you would be better off dead or of hurting yourself in some way

Anxiety screener
0 = No
1 = Yes

10. In the last 4 weeks have you suddenly had an anxiety attack—feeling fear or panic? (go to Question #11 if the answer to #10 is “no”)
   a. Has this ever happened before?
   b. Do some of these attacks come suddenly out of the blue—that is, in situations where you didn’t expect to be nervous or uncomfortable?
   c. Do these attacks bother you a lot or are you worried about having another attack?
   d. During your last bad anxiety attack, did you have symptoms like shortness of breath, sweating, your heart racing or pounding, dizziness or faintness, tingling or numbness, or nausea or upset stomach?

0 = Not at all difficult
1 = Somewhat difficult
2 = Very difficult
3 = Extremely difficult

11. If you checked off any problems on this questionnaire so far, how difficult have these problems made it for you to do your work, take care of things at home, or get along with other people?

0 = Not at all difficult
1 = Somewhat difficult
2 = Very difficult
3 = Extremely difficult

Total Score _______

Note: Reprinted from Spitzer et al. Copyright held by Pfizer Inc, but may be photographed ad libitum.

Figure 6. Rates of Depression in Patients With Medical Illness

<table>
<thead>
<tr>
<th>Condition</th>
<th>Prevalence Rate</th>
</tr>
</thead>
<tbody>
<tr>
<td>Parkinson’s Disease</td>
<td></td>
</tr>
<tr>
<td>Migraine or Severe Headache</td>
<td></td>
</tr>
<tr>
<td>Diabetes</td>
<td></td>
</tr>
<tr>
<td>Cerebrovascular Accident</td>
<td></td>
</tr>
<tr>
<td>Severe CAD or MI</td>
<td></td>
</tr>
<tr>
<td>Cancer</td>
<td></td>
</tr>
</tbody>
</table>

Data from references 34, 35, 38, 41, and 43–46. Abbreviations: CAD = coronary artery disease; MI = myocardial infarction.

and/or anxiety disorders. Studies indicate that 20% to 50% of patients with many common medical illnesses will develop depression (see Figure 6 for examples). The rates for anxiety disorders are similarly high.

Despite these high rates of concurrent illness, the presence of a primary general medical diagnosis markedly reduces the detection rate of depression and anxiety disorders: only 1 of every 5 patients who present with depression or anxiety and medical comorbidity receive appropriate treatment for their psychiatric illness. This low detection rate is unfortunate because more than 80% of these patients, in any given year, will visit their primary care physicians. In contrast, less than 2% will see a psychiatrist or other mental health specialist without having first visited their primary care physician.

The consequences of unrecognized anxiety and depressive disorders are many, including a significant increase in the utilization of medical services, as well as increased rates of disability given equivalent levels of medical illness severity. In addition, unrecognized anxiety or depressive comorbidity has been shown to lead to a 3-fold increased likelihood of nonadherence to treatment. For example, among diabetics, the presence of major depression is associated with significantly poorer glycemic control.

Depression appears to represent an especially important risk factor for the development of some types of general medical illness, most notably vascular disease. Longitudinal data on elderly hypertensive patients suggest that for every 5-point increase in score on the CES-D, there is an 18% increase in the risk of myocardial infarction (MI) or stroke and a 25% increase in overall mortality. The prevalence rate of major depression following an MI is 20%. Additionally, depression that develops post-MI is associated with a significantly increased risk of subsequent MI and death, with adjusted odds ratios for the
latter in the range of 4 to 6.\textsuperscript{34,51,52} It is still an open question as to whether aggressive early treatment of depression in the immediate post-MI period will lead to more favorable outcomes, including improved functioning and quality of life and reduced mortality. Preliminary research suggests that early treatment intervention may be both safe and efficacious.\textsuperscript{53}

**MOOD/ANXIETY DISORDER COMORBIDITY: PHARMACOLOGIC TREATMENT**

SSRIs have become the first-line treatment for both major depression and the anxiety disorders. Table 2 summarizes the diagnoses for which the SSRIs and other new generation antidepressants have U.S. Food and Drug Administration (FDA)–approved indications. As can be seen, paroxetine and sertraline represent the most broad-spectrum antidepressants in terms of the range of anxiety disorders for which efficacy has been established. Paroxetine has recently shown positive results for PTSD and GAD,\textsuperscript{54,55} while double-blind studies of sertraline in GAD are currently underway.

Because of the relative lack of treatment research on comorbidity, no medication to date has been approved by the FDA for the treatment of comorbid major depressive disorder and an anxiety disorder (Figure 1, panel C). However, there are controlled studies of sertraline in the treatment of major depression and comorbid panic disorder (U. Lepola, M.D., Ph.D.; M. Arató, M.D., Ph.D., D.Sc.; C. Austin, M.D., unpublished data, 2002), OCD,\textsuperscript{56} and PTSD.\textsuperscript{57,58} In addition, results of a study of venlafaxine for the treatment of major depression and GAD have recently been reported.\textsuperscript{59}

The question at hand is, If an antidepressant has demonstrated efficacy in each disorder individually, is that result sufficient to ensure efficacy in both disorders when they occur comorbidly? The answer to this is unclear. While we may be inclined to accept such indirect evidence of efficacy, it is no substitute for actual controlled trials.

There are several reasons why clinical trials in patients with comorbid depression and anxiety are vital and why direct evidence of efficacy is important for appropriate treatment. It is possible that the antidepressant simply may not work as well in patients with combined anxiety and depression. For example, there is ample evidence that imipramine is effective for the treatment of both major depression and panic disorder.\textsuperscript{60,61} Yet the first study ever conducted that evaluated its efficacy in the treatment of comorbid depression and panic disorder did not confirm its efficacy in both disorders.\textsuperscript{62} Direct study of efficacy in patients with comorbid depression and anxiety is also important because the dose requirements, the time to response, and the minimally effective duration of acute treatment may all be different. In addition, information is needed on when, and to what extent, there may be a discordance between the response of one or the other comorbid disorder and how to effectively treat patients in whom one disorder has responded, but the other has not.

Figure 7 illustrates the efficacy results from one of the few available comorbidity studies (U. Lepola, M.D., Ph.D.; M. Arató, M.D., Ph.D., D.Sc.; C. Austin, M.D., unpublished data, 2002). Both sertraline and imipramine demonstrated equivalent efficacy in the treatment of both panic disorder and major depression. Approximately 1 of 4 patients discontinued imipramine due to side effects, while only half that number (12%) discontinued sertraline due to side effects (p < .05). Interestingly, 40% of the pa-

### Table 2. FDA-Approved Indications for SSRIs and Atypical Antidepressants\textsuperscript{5}

<table>
<thead>
<tr>
<th>Antidepressant</th>
<th>Depressive Disorders</th>
<th>Anxiety Disorders</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>MDD</td>
<td>PMDD</td>
</tr>
<tr>
<td>Fluoxetine</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>Sertraline</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>Paroxetine</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>Citalopram</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>Venlafaxine</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>Nefazodone</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>Mirtazapine</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>Bupropion</td>
<td>✓</td>
<td>✓</td>
</tr>
</tbody>
</table>

\textsuperscript{5}This list includes indications currently under review. Abbreviations: FDA = U.S. Food and Drug Administration, GAD = generalized anxiety disorder, MDD = major depressive disorder, PMDD = premenstrual dysorphic disorder, PTSD = posttraumatic stress disorder, SSRI = selective serotonin reuptake inhibitor. Imipramine also has demonstrated efficacy, based on 2 or more positive, double-blind, placebo-controlled trials for MDD, dysthmic disorder, and panic disorder, and clomipramine has demonstrated efficacy in MDD, panic disorder, and GAD.

---

**Figure 7. Time Course of Improvement in (A) MADRS Score and (B) Panic Attack Frequency During 26 Weeks of Treatment of Concurrent Panic Disorder and Major Depression\textsuperscript{a}**

- **A.** Time course of improvement in MADRS score during 26 weeks of treatment.
  - Imipramine (N = 68): MADRS score decreased significantly from baseline to week 26 (p < .05).
  - Sertraline (N = 135): MADRS score also decreased significantly from baseline to week 26 (p < .05).
- **B.** Time course of improvement in panic attack frequency during 26 weeks of treatment.
  - Both imipramine and sertraline demonstrated significant reductions in panic attack frequency from baseline to week 26.

tients who discontinued each drug were responders at the time of discontinuation. These patients are at significantly greater risk of relapse and represent one of the chief clinical challenges in the treatment of comorbidity: the long-term treatment.

The clinical presentations of a major depressive episode or an individual anxiety disorder are far more thoroughly studied than the comorbid presentation of these disorders. Figure 1, panels A and B, is a diagrammatic illustration of a clinical presentation of patients who present with one diagnosis, major depressive disorder or anxiety disorder, and subsyndromal symptoms of the other diagnosis. There have been many reports demonstrating the efficacy of SSRIs and newer antidepressants in anxious depression, but few report head-to-head comparisons, so it is difficult to make within-class treatment decisions based solely on efficacy. One of the few studies that has reported a direct comparison (Figure 8) found equivalent antidepressant efficacy at the end of acute treatment for fluoxetine, sertraline, and paroxetine.63

Almost no literature is available that evaluates the efficacy of SSRIs or other antidepressants in the treatment of subsyndromal depression/anxiety. For many years, this group of patients was treated symptomatically with benzodiazepines, but some studies suggest that this treatment strategy is no better than modest amounts of supportive counseling and may actually iatrogenically contribute to the development of major depression, as well as the development of physical dependence on benzodiazepines.66 At present, no study of low-dose SSRI therapy is available in this patient population.

There is one final but important note about the pharmacologic treatment of depression and anxiety in primary care, whether the disorder occurs individually or comorbidly. Virtually all of the published treatment research is based on studies conducted in specialty psychiatry set-

Figure 8. Comparison of Treatment Outcome Among Selective Serotonin Reuptake Inhibitors in Anxious Depression.6*

<table>
<thead>
<tr>
<th>Responder/Remitter</th>
<th>Fluoxetine (N = 35)</th>
<th>Sertraline (N = 43)</th>
<th>Paroxetine (N = 30)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Responders</td>
<td>73%</td>
<td>86%</td>
<td>62%</td>
</tr>
<tr>
<td>Remitters</td>
<td>87%</td>
<td>77%</td>
<td>57%</td>
</tr>
</tbody>
</table>

*Data from Fava et al.63 No significant between-drug differences in either response or remission rate.

In addition to efficacy, the extensive use of the newer antidepressants in primary care depends on 2 factors: simplicity of use and a generally favorable safety and tolerability profile. The 2 factors are related since simplicity of use refers not only to the ease of a once-a-day dosing schedule (nefazodone is an exception) and an uncomplicated titration schedule but also to the fact that the newer antidepressants have very wide therapeutic windows and therefore are relatively safe in terms of overdose risk. As a result, treatment with SSRIs, for example, does not require the limiting of prescriptions to small numbers of pills and the close spacing of physician visits that treatment with the tricyclics require. Simplicity of use also refers to the generally low drug-drug interaction profile of most SSRIs and other newer antidepressants.

The safety and tolerability profile of the newer antidepressants is especially appealing in the primary care setting because of the information summarized above concerning the frequency of occurrence and the clinical implications of depression/anxiety comorbidity. Patients with concurrent depression and anxiety disorders have a longer time to response and higher risk of recurrence than patients presenting with either disorder alone. As a result, patients with depression/anxiety comorbidity are likely to benefit from a longer-term course of treatment. It is well established that compliance with long-term treatment is directly proportional to both simplicity of use and tolerability.

A related group of patients in whom safety and tolerability are paramount is the elderly. This is due, in part, to the markedly increased likelihood of additional drug treatment, as well as physiologic changes in drug metabolism and excretion.

From a pharmacokinetic standpoint, the SSRIs and other newer antidepressants have a relatively clean profile. Yet, as can be seen in Table 3, there are within-class differences that need to be kept in mind. Fluoxetine has a substantially longer half-life, which is further extended by the long half-life of its clinically active metabolite norfluoxetine. A consequence of this long half-life is that fluoxetine requires a much longer washout before it is safe to switch to drugs whose concomitant use with fluoxetine is contraindicated. In the case of intolerability, it may take longer to clear the drug from the system.

TOLERABILITY AND SAFETY

In addition to efficacy, the extensive use of the newer antidepressants in primary care depends on 2 factors: simplicity of use and a generally favorable safety and tolerability profile. The 2 factors are related since simplicity of use refers not only to the ease of a once-a-day dosing schedule (nefazodone is an exception) and an uncomplicated titration schedule but also to the fact that the newer antidepressants have very wide therapeutic windows and therefore are relatively safe in terms of overdose risk. As a result, treatment with SSRIs, for example, does not require the limiting of prescriptions to small numbers of pills and the close spacing of physician visits that treatment with the tricyclics require. Simplicity of use also refers to the generally low drug-drug interaction profile of most SSRIs and other newer antidepressants.

The safety and tolerability profile of the newer antidepressants is especially appealing in the primary care setting because of the information summarized above concerning the frequency of occurrence and the clinical implications of depression/anxiety comorbidity. Patients with concurrent depression and anxiety disorders have a longer time to response and higher risk of recurrence than patients presenting with either disorder alone. As a result, patients with depression/anxiety comorbidity are likely to benefit from a longer-term course of treatment. It is well established that compliance with long-term treatment is directly proportional to both simplicity of use and tolerability.

A related group of patients in whom safety and tolerability are paramount is the elderly. This is due, in part, to the markedly increased likelihood of additional drug treatment, as well as physiologic changes in drug metabolism and excretion.

From a pharmacokinetic standpoint, the SSRIs and other newer antidepressants have a relatively clean profile. Yet, as can be seen in Table 3, there are within-class differences that need to be kept in mind. Fluoxetine has a substantially longer half-life, which is further extended by the long half-life of its clinically active metabolite norfluoxetine. A consequence of this long half-life is that fluoxetine requires a much longer washout before it is safe to switch to drugs whose concomitant use with fluoxetine is contraindicated. In the case of intolerability, it may take longer to clear the drug from the system.

TOLERABILITY AND SAFETY

In addition to efficacy, the extensive use of the newer antidepressants in primary care depends on 2 factors: simplicity of use and a generally favorable safety and tolerability profile. The 2 factors are related since simplicity of use refers not only to the ease of a once-a-day dosing schedule (nefazodone is an exception) and an uncomplicated titration schedule but also to the fact that the newer antidepressants have very wide therapeutic windows and therefore are relatively safe in terms of overdose risk. As a result, treatment with SSRIs, for example, does not require the limiting of prescriptions to small numbers of pills and the close spacing of physician visits that treatment with the tricyclics require. Simplicity of use also refers to the generally low drug-drug interaction profile of most SSRIs and other newer antidepressants.

The safety and tolerability profile of the newer antidepressants is especially appealing in the primary care setting because of the information summarized above concerning the frequency of occurrence and the clinical implications of depression/anxiety comorbidity. Patients with concurrent depression and anxiety disorders have a longer time to response and higher risk of recurrence than patients presenting with either disorder alone. As a result, patients with depression/anxiety comorbidity are likely to benefit from a longer-term course of treatment. It is well established that compliance with long-term treatment is directly proportional to both simplicity of use and tolerability.

A related group of patients in whom safety and tolerability are paramount is the elderly. This is due, in part, to the markedly increased likelihood of additional drug treatment, as well as physiologic changes in drug metabolism and excretion.

From a pharmacokinetic standpoint, the SSRIs and other newer antidepressants have a relatively clean profile. Yet, as can be seen in Table 3, there are within-class differences that need to be kept in mind. Fluoxetine has a substantially longer half-life, which is further extended by the long half-life of its clinically active metabolite norfluoxetine. A consequence of this long half-life is that fluoxetine requires a much longer washout before it is safe to switch to drugs whose concomitant use with fluoxetine is contraindicated. In the case of intolerability, it may take longer to clear the drug from the system.
The potential for drug-drug interactions is summarized in the P450 column of Table 3. Drug-drug interactions may come from the impact of a coadministered drug that inhibits a cytochrome P450 isoenzyme on SSRI metabolism or, conversely, the degree to which an SSRI inhibits P450 isoenzymes, thereby altering the metabolism and blood levels of coadministered drugs. Sertraline and citalopram have the “cleanest” pharmacokinetic profile in terms of short-to-intermediate half-life, lack of clinically relevant active metabolites, linear pharmacokinetics, and lack of potential for drug-drug interactions, although relatively few P450 pharmacokinetic data in humans are available at this point for citalopram. The literature is extensive that reviews the potential drug interaction profiles of the SSRIs and is beyond the scope of the current article.71 It should be emphasized, though, that the actual incidence of clinically relevant toxicity due to SSRI drug interactions is uncertain and may be low.

Tolerability of SSRI s and Newer Antidepressants

The SSRIs and other newer antidepressants have a generally favorable side effect profile. During long-term treatment (3 months or longer), tolerance develops to the majority of adverse events observed early in treatment, and they disappear or become much milder. But other adverse events may become more prominent over the course of long-term therapy, not so much because of increased severity, but because patients may be less able or willing to tolerate these adverse events over time.

Perhaps the most prominent example of an adverse event leading to discontinuation during long-term antidepressant therapy is clinically significant weight gain. In a study of imipramine treatment of panic disorder, weight gain was the single biggest reason for medication discontinuation.72 Many of the SSRIs and newer antidepressants appear to offer advantages over tricyclic antidepressants and monoamine oxidase inhibitors in terms of weight gain, but little is known about the comparative differences in weight gain among the newer antidepressants themselves. Figure 9 summarizes the results of a study comparing the effects of fluoxetine, sertraline, and paroxetine on weight during long-term treatment. For both fluoxetine and sertraline, change in weight was not significantly different from baseline. However, at least 1 of every 4 patients treated with paroxetine gained > 7% of body weight after 26 to 32 weeks of treatment.73 The reason why treatment with paroxetine is more likely to be associated with significant weight gain is uncertain, but may relate to its more prominent anticholinergic effect.74

Another adverse event that might be tolerated in the short run, but with the potential to lead to discontinuation in the long run, is sexual dysfunction. Nefazodone, bupropion, and mirtzapine appear to have the most favorable profile in terms of sexual dysfunction among all the newer agents.75,76 Not much is known about long-term outcome in patients who develop sexual dysfunction during acute treatment with SSRIs. There is evidence that sexual dysfunction is, at least in part, dose related and that reductions in dose will frequently alleviate sexual dysfunction. An analysis of long-term data from a study of sertraline in the treatment of depression has found that tolerance develops to sexual dysfunction in the majority of patients.77 One would assume that tolerance may be a class effect, but more data are needed to confirm this. There are few direct comparisons of the impact of SSRIs on sexual functioning based on systematic assessment. In one such study, no significant difference was found for the incidence of sexual dysfunction with sertraline (13.5%) versus citalopram (20%).78

Table 3. Pharmacokinetic Profile of Marketed SSRIs and Atypical Antidepressants

<table>
<thead>
<tr>
<th>Antidepressant</th>
<th>Half-Life</th>
<th>Clinically Relevant Active Metabolite?</th>
<th>Plasma Level Increase Nonlinear (i.e., increases faster than dose) vs Linear</th>
<th>Clinically Relevant P450 Inhibition by Medication</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fluoxetine</td>
<td>4–8 d</td>
<td>Yes</td>
<td>Nonlinear</td>
<td>CYP2D6</td>
</tr>
<tr>
<td>Sertraline</td>
<td>26 h</td>
<td>No</td>
<td>Linear</td>
<td>Minimal CYP2D6</td>
</tr>
<tr>
<td>Paroxetine</td>
<td>18 h</td>
<td>No</td>
<td>Nonlinear</td>
<td>CYP2D6</td>
</tr>
<tr>
<td>Citalopram</td>
<td>35 h</td>
<td>No</td>
<td>Nonlinear</td>
<td>Uncertain</td>
</tr>
<tr>
<td>Venlafaxine</td>
<td>3–11 h</td>
<td>Yes</td>
<td>Linear</td>
<td>Minimal-to-no CYP2D6</td>
</tr>
<tr>
<td>Nefazodone</td>
<td>2–8 h</td>
<td>Yes</td>
<td>Nonlinear</td>
<td>CYP3A4</td>
</tr>
<tr>
<td>Mirtazapine</td>
<td>20–40 h</td>
<td>Yes</td>
<td>Nonlinear for R-enantiomer</td>
<td>Minimal</td>
</tr>
<tr>
<td>Bupropion</td>
<td>10–24 h</td>
<td>Yes</td>
<td>Linear</td>
<td>High CYP2D6 inhibition</td>
</tr>
</tbody>
</table>

*Data from references 68–70. Abbreviations: CYP = cytochrome P450, SSRI = selective serotonin reuptake inhibitor.

Figure 9. Comparison of the Effect of Long-Term Selective Serotonin Reuptake Inhibitor Treatment on Weight

© Copyright 2001 Physicians Postgraduate Press, Inc.
Figure 10. Effect of Abrupt Selective Serotonin Reuptake Inhibitor Discontinuation on Occurrence of Withdrawal Symptoms

- Reprinted with permission from Michelson et al.79

*p < .05 for fluoxetine vs. paroxetine; other drug differences were not significant.

EFFECTS OF MISSING DOSES AND ABRUPT TREATMENT DISCONTINUATION

One of the practical aspects of medication treatment with SSRIs and other antidepressants is the fact that patients, for various reasons, may not take their medication for several days. This form of temporary noncompliance leads to unplanned visits to the emergency room or to night or weekend calls to a physician’s answering service. Such abrupt medication discontinuation may also occur when there is some medical reason for rapidly stopping treatment.

Several studies have directly compared the effect of abruptly discontinuing SSRI treatment.79,80 As might be expected on the basis of its very long half-life, fluoxetine had no discontinuation effects whatsoever (Figure 10). Even though paroxetine and sertraline have similar elimination half-lives, sertraline was found to have milder withdrawal effects after abrupt discontinuation of treatment than paroxetine, possibly because of the anticholinergic effects associated with the latter drug.79,80 The potential for a withdrawal syndrome after discontinuing paroxetine has recently been added to its product labeling.

CONCLUSION

The co-occurrence of depression and anxiety disorders is extremely common in primary care. The clinical implications of depression/anxiety comorbidity include increased risk of suicide, increased risk of psychiatric hospitalization, increased disability, decreased compliance with treatment of medical illness, and markedly increased utilization of medical services. Patients with depression/anxiety comorbidity tend to have more chronic and recurrent forms of illness that require long-term treatment. This puts a premium on medications, such as the SSRIs, that have broad-spectrum efficacy (notably sertraline and paroxetine), wide therapeutic windows, and favorable pharmacokinetic and drug-interaction profiles (such as sertraline and citalopram) and are well tolerated in terms of side effects (such as weight gain), contributing to compliance with long-term treatment.

Despite the high prevalence and important clinical implications of depression/anxiety comorbidity, very little prospective treatment research is available. The appropriate recognition and treatment of depression and anxiety disorder comorbidity truly represent the last therapeutic frontier in the management of psychiatric illness in the primary care setting.

REFERENCES

76. Hirschfeld RM. Sexual dysfunction in depression: disease- or drug-related? Depress Anxiety 1998;7(suppl 1):21–23